Wah Yan is a Director as part of Certara’s Evidence & Access group. Wah joins from Novo Nordisk, where he spent four years supporting the development of the company’s long-term enterprise strategy. As a strategist, Wah continually tackles one of healthcare’s biggest challenges – how do you build sustainable business models in the face of accelerating change in US healthcare. He combines this perspective with Certara’s unique data capabilities & tech platforms to empower clients not only to lower the cost of innovation, but to maximize realized value from those investments.